Recent research sheds light on how changes in the chemical structure of a protein called Interleukin-6 affect lung cancer’s ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...

Biologics targeting interleukin (IL)-12, IL-23, and IL-17 may have valuable safety benefits among older adults with psoriatic disease, as a lower rate of serious infection was observed among these ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting interleukin (IL)-12, IL-23, or IL-17 were associated with a lower rate of ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Interleukin 2 (IL-2) is the only systemic treatment currently available that is capable of curing patients with metastatic renal cell cancer (RCC). The first indications that IL-2 could mediate ...

Oruka Therapeutics, Inc.’s ORKA share price has dipped by 6.19%, which has investors questioning if this is right time to buy ...

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden and debilitating hives and recurring itch.

A new study presented at ESCMID Global 2025 highlights interleukin-6 (IL-6) as a fast, accurate biomarker for early sepsis detection in neonates, children, and pregnant women.

In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way ...